Fundacja na Rzecz Rozwoju Biotechnologii i Genetyki POLBIOGEN
ul. Jugosłowiańska 57, 60-159 Poznań

Fundacja na Rzecz Rozwoju Biotechnologii i Genetyki
POLBIOGEN jest niezależną, samodzielną finansowo
instytucją powołaną do pełnienia misji wspierania
biotechnologii i genetyki oraz realizowania projektów
badawczych w tych dziedzinach.


Foundation for the Development of Biotechnology and Genetics  POLBIOGEN is the organizer and co-organizer and supports financially numerous scientific events.

Vaccinations against COVID-19

Representatives of the POLBIOGEN Foundation participated in the preparation of the book Biotechnologia 2020. What we ask most often, in which they presented the latest achievements of biotechnology. Among them, unexpectedly, there were issues related to the SARRS-CoV-2 virus pandemic, which leads to the COVID-19 disease. Research on the COVID-19 vaccine began immediately after the publication of the genetic sequence of the SARS-CoV-2 coronavirus. On January 11, 2020, the genetic sequence of the SARS-CoV-2 coronavirus causing COVID-19 was published. Currently, more than 50 vaccines are in clinical trials and three times more in preclinical trials. Since then, extensive research and development has been carried out around the world to develop a vaccine against this disease. The humanitarian and economic impacts of the COVID-19 pandemic have provided extraordinary motivation in vaccine research, making the first vaccine prototypes at an unprecedented pace ready for human clinical trials (16 March 2020). Scientists are testing various technologies, some of which have not previously been used in a licensed vaccine. On October 15, 2020, the European Commission presented a communication on “Preparedness for vaccination strategy and vaccine introduction against COVID-19″, in which it introduced a temporary “fast-track” to obtain safe vaccines against COVID-19, assuming withdrawal from the clinical trial phase from a prior environmental risk assessment on genetically modified organisms (GMOs) as required by EU law. Packaging, labeling, storage, transportation, destruction, disposal, distribution, delivery, administration or use of investigational medicinal products in humans has also been facilitated. The regulation will remain in place until COVID-19 is considered a pandemic by the World Health Organization (WHO) or the European Commission deems there to be a public health threat from COVID-19. The European Medicines Agency has approved the BioNTech-Pfizer vaccine for use in Europe, more are pending approval from AstraZeneca, Sanofi-GSK, Johnson & Johnson, CureVac and Moderna. The US Food and Drug Administration has already approved two vaccines, BioNTech-Pfizer and Moderna.


IX National Scientific Conference “Insight into Cancer”, Lublin, 4.09.2020

On September 4, 2020, the Students’ Scientific Association of Cancer Genetics at the Medical University of Lublin organized the 9th edition of the National Conference “Insight into Cancer” in the online form. The conference was aimed at students and young scientists. The aim of the conference was to present the molecular mechanisms responsible for the development of neoplastic diseases and to present the progress in their diagnosis and treatment. As every year, the POLBIOGEN Foundation supported the activity of young researchers.


On May 17-19, 2010 in Jastrzębiec/ near Warsaw the Foundation organized workshop on Analysis of genomic and mitochondrial DNA of extinct and endangered species. more…

The Foundation POLBIOGEN co-organized the 5th Conference of Polish Society for Clinical Pharmacology and Therapeutics entitled ‘Molecular methods – from theory to practical implementation that was held in Poznań, 19th November 2009.

The Foundation offers a financial support for the participants of Summer Schools organized  by the  Department of Biochemistry and Biotechnology of Poznan University of Life Sciences